Paper 33 - SAFETY AND EARLY EFFICACY OF VT3989, A TEAD INHIBITOR, IN PATIENTS WITH ADVANCED EPITHELIOID HEMANGIOENDOTHELIOMA (EHE): A PHASE I/II STUDY

Author(s)

• 

  Candace L. Haddox, MD

  Physician
  Dana Farber Cancer Institute
  Boston, Massachusetts, United States

  Slides

Co-Author(s)

• 

  Mrinal M. Gounder, MD

  Associate Attending Physician
  Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College
  New York, New York, United States
• TY

  Timothy A. Yap, MBBS, PhD, FRCP

  Associate Professor
  MD Anderson Cancer Center
  Houston, Texas, United States
• MO

  Michael Offin, MD

  Memorial Sloan Kettering Cancer Center
  New York, New York, United States
• DK

  David J. Kwiatkowski, MD, PhD

  Dana Farber Cancer Institute
  Boston, Massachusetts, United States
• RK

  Robert Kratzke, MD

  Professor of Medicine
  University of Minnesota Masonic Cancer Center
  Minneapolis, Minnesota, United States
• ID

  Ibiayi Dagogo-Jack, MD

  Massachusetts General Hospital
  Boston, Massachusetts, United States
• 

  Anthony W. Tolcher, M.D., FRCPC (he/him/his)

  CEO and Founder of NEXT Oncology
  NEXT Oncology
  San Antonio, Texas, United States
• JD

  Jayesh Desai, MBBS, FRACP

  Medical Oncologist
  Peter MacCallum Cancer Center
  Melbourne, Victoria, Australia
• AB

  Amy L. Body, MBBS, FRACP

  Monash Medical Centre
  Melbourne, Victoria, Australia
• MM

  Michael Millward, MBBS

  Linear Clinical Research
  Nedlands, Western Australia, Australia
• HK

  Hedy L. Kindler, MD

  The University of Chicago Medicine
  Chicago, Illinois, United States
• TT

  Tracy T. Tang, PhD

  Vivace Therapeutics
  San Mateo, California, United States
• YL

  Yufeng Li, PhD

  Vivace
  San Mateo, California, United States
• NS

  Neelesh Sharma, MD PhD

  Vivace Therapeutics
  Livingston, New Jersey, United States
• 

  Gregory M. Cote, MD PhD (he/him/his)

  Associate Professor of Medicine
  Mass General Cancer Center, Massachusetts General Hospital
  Boston, Massachusetts, United States